AIDOT (formerly Buzzpole), an AI-based medical ICT company, announced on the 29th that it has been selected as one of the 2020 "Seoul's Deal," a joint initiative by the Seoul Metropolitan Government and the Invest Seoul Center to attract foreign investment.

AIDOT has developed the world's first AI-based portable carotid ultrasound device and solution capable of preemptive stroke risk screening, and has received official approval for the "CRIS (Multi-Institutional Multi-Clinical Initiative)."

The company is conducting the test with co-developers Professor Jin-Pyeong Jeon's team from the Department of Neurosurgery at Hallym University Chuncheon Sacred Heart Hospital and neurosurgery faculty from four university hospitals.

In March of this year, AIDOT signed an exclusive solution supply agreement with Gynius, a Swedish company specializing in colposcopy cameras for cervical cancer screening. All overseas certifications, including those from the CFDA, CE, and FDA, have been resolved. For the Chinese market, AIDOT signed an initial system export contract worth approximately $100,000 with the Chinese subsidiary of S-Net Systems, focusing on Beijing.

Additionally, AIDOT expects to generate $4 million (KRW 4 billion) in exports this year by supplying its cervical cancer diagnosis system, Cerviray A.I., to Southeast Asia.

With this designation as a promising company, AIDOT plans to accelerate its overseas expansion by attracting foreign investment. Its goal is to produce results that can immediately generate results both domestically and internationally.

AIDOT CEO Jeong Jae-hoon stated, "As an AI medical ICT company, AIDOT has not focused solely on appearances. Instead, we have strengthened our internal capabilities through collaborations with leading Korean medical professionals, strengthening our AI research center's capabilities, and developing business models in the medical sector. By developing an AI medical ICT business model that is appealing to medical professionals at home and abroad, we will achieve significant results with AI-based medical solutions overseas."

June 29, 2020, 10:15 AM / JoongAng Ilbo Health Media / Reporter Park Jeong-ryeol park.jungryul@joongang.co.kr